<DOC>
	<DOCNO>NCT00953108</DOCNO>
	<brief_summary>In former study investigator research group investigator could also demonstrate acute inhibitory effect antidepressant mirtazapine ACTH cortisol release normal control ( Schüle et al . 2002 ) , likely mediate via antagonism central 5-HT2- H1-receptors . In contrast mirtazapine , serotonin norepinephrine reuptake inhibit antidepressant acutely stimulate ACTH cortisol secretion ( Schüle 2007 ) . The investigator also perform study depress patient treat either mirtazapine reboxetine use serial dexamethasone/CRH test ( week 0 , 1 , 5 ) parameter HPA axis activity . Mirtazapine , norepinephrine reuptake inhibitor reboxetine able significantly reduce HPA axis activity already within one week ( Schüle et al . 2006 ) . Mirtazapine know earlier onset antidepressant action SSRIs sertraline ( Behnke et al . 2003 ) antidepressant dual mechanism action venlafaxine ( Benkert et al . 2006 ) , possibly due rapid inhibition HPA axis activity unipolar depress patient . Since mirtazapine quetiapine similar effect HPA system healthy male volunteer ( i.e . inhibition ACTH cortisol secretion ) , rapid attenuation HPA axis activity also expect quetiapine XR treatment depress patient . Therefore , present study investigator goal investigate whether quetiapine fumarate XR dosage 300 mg per day impact HPA axis activity unipolar depress patient , measure serial dexamethasone/CRH test ( week 0 , 1 , 5 ) salivary cortisol profile whether putative effect quetiapine XR HPA system relate antidepressant efficacy .</brief_summary>
	<brief_title>Quetiapine Prolong , Escitalopram Hypothalamic-pituitary-adrenocortical ( HPA ) Axis Activity Depressed Patients</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Inclusion criterion : For inclusion study patient must fulfil follow criterion : 1 . Inpatients ( admission hospital occur independently study participation ) 2 . Provision write informed consent 3 . A diagnosis major depression Diagnostic Statistical Manual Mental Disorders Fourth Edition ( DSMIV ) ( unipolar depression : 296.2 , 296.3 ) 4 . Female male patient age 18 65 year 5 . Female patient childbearing potential must negative serum human chorionic gonadotropin ( hCG ) pregnancy test enrolment e willing use reliable method birth control ( i.e . barrier method , oral contraceptive , implant , dermal contraception , longterm injectable contraceptive , intrauterine device , tubal litigation ) study . 6 . Able understand comply requirement study judged investigator . 7 . A sum score least 18 21item version Hamilton Depression Rating Scale ( 21HAMD ) Exclusion criterion : Any follow regarded criterion exclusion study : 1 . Pregnancy lactation 2 . Any DSMIV Axis I disorder define inclusion criterion 3 . Patients , opinion investigator , pose imminent risk suicide danger self others 4 . Known intolerance lack response quetiapine fumarate and/or escitalopram , judge investigator 5 . Use follow cytochrome P450 3A4 inhibitor 14 day precede enrolment include limited : ketoconazole , itraconazole , fluconazole , erythromycin , clarithromycin , troleandomycin , indinavir , nelfinavir , ritonavir , fluvoxamine saquinavir 6 . Use follow cytochrome P450 3A4 inducer 14 day precede enrolment include limited : phenytoin , carbamazepine , barbiturate , rifampin , St. John 's Wort , glucocorticoids 7 . Use monoamine oxidase inhibitor ( MAOIs ) serotonergic drug ( e.g . triptans ) 14 day precede enrolment 8 . Use oral anticoagulant 14 day precede enrolment 9 . History bleed disorder . 10 . Use drug mainly metabolize cytochrome P450 2D6 low therapeutic index ( e.g . flecainide , propafenone , metoprolol ) 14 day precede enrolment 11 . Administration depot antipsychotic injection within one dose interval ( depot ) randomisation 12 . Substance alcohol dependence enrolment ( except dependence full remission , except caffeine nicotine dependence ) , define DSMIV criterion 13 . Opiates , amphetamine , barbiturate , cocaine , cannabis , hallucinogen abuse DSMIV criterion within 4 week prior enrolment 14 . Medical condition would affect absorption , distribution , metabolism , excretion study treatment 15 . Unstable inadequately treat medical illness ( e.g . congestive heart failure , angina pectoris , hypertension ) judge investigator 16 . Involvement plan conduct study 17 . Previous enrolment randomisation treatment present study . 18 . Participation another drug trial within 4 week prior enrolment study long accordance local requirement 19 . A patient Diabetes Mellitus ( DM ) fulfil one follow criterion : Unstable DM define enrolment glycosylated hemoglobin ( HbA1c ) &gt; 8.5 % . Admitted hospital treatment DM DM relate illness past 12 week . Not physician care DM Physician responsible patient 's DM care indicate patient 's DM control . Physician responsible patient 's DM care approve patient 's participation study Has dose oral hypoglycaemic drug ( ) and/or diet 4 week prior randomisation . For thiazolidinediones ( glitazones ) period le 8 Weeks . Taking insulin whose daily dose one occasion past 4 week 10 % mean dose precede 4 week Note : If diabetic patient meet one criterion , patient exclude even treat physician believe patient stable participate study . 20 . An absolute neutrophil count ( ANC ) 1.5 x 109 per liter 21 . Abnormal laboratory parameter clinical relevance enrolment 22 . Abnormal blood pressure , abnormal electrocardiogram , and/or abnormal electroencephalogram clinical relevance enrolment 23 . Psychotropic drug within 3 day throughout study exception zopiclon ( 7.5 mg per day ) case sleep difficulty lorazepam ( 2 mg per day ) case inner tension anxiety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>